Epileptic Targets and Drugs : A Mini-Review
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Epilepsy is a neurological disease affected by an imbalance of inhibitory and excitatory signaling in the brain.
INTRODUCTION: In this disease, the targets are active in pathophysiology and thus can be used as a focus for pharmacological treatment.
METHODS: Several studies demonstrated the antiepileptic effect of drugs acting on the following targets: N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, voltage-gated calcium channel (Cav), Gamma aminobutyric acid transporter type 1 (GAT1), voltage-gated sodium channels (Nav), voltage-gated potassium channel of the Q subfamily (KCNQ) and Gamma aminobutyric acid type A (GABAA) receiver.
RESULTS: These studies highlight the importance of molecular docking.
CONCLUSION: Quantitative Structure-Activity Relationship (QSAR) and computer aided drug design (CADD) in predicting of possible pharmacological activities of these targets.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Current drug targets - 24(2023), 3 vom: 27., Seite 212-224 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rodrigues, Teresa Carolliny Moreira Lustoza [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
56-12-2 |
|---|
| Anmerkungen: |
Date Completed 16.03.2023 Date Revised 21.03.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1389450123666220927103715 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346886309 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346886309 | ||
| 003 | DE-627 | ||
| 005 | 20231226032524.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389450123666220927103715 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM346886309 | ||
| 035 | |a (NLM)36173074 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rodrigues, Teresa Carolliny Moreira Lustoza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Epileptic Targets and Drugs |b A Mini-Review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.03.2023 | ||
| 500 | |a Date Revised 21.03.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Epilepsy is a neurological disease affected by an imbalance of inhibitory and excitatory signaling in the brain | ||
| 520 | |a INTRODUCTION: In this disease, the targets are active in pathophysiology and thus can be used as a focus for pharmacological treatment | ||
| 520 | |a METHODS: Several studies demonstrated the antiepileptic effect of drugs acting on the following targets: N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, voltage-gated calcium channel (Cav), Gamma aminobutyric acid transporter type 1 (GAT1), voltage-gated sodium channels (Nav), voltage-gated potassium channel of the Q subfamily (KCNQ) and Gamma aminobutyric acid type A (GABAA) receiver | ||
| 520 | |a RESULTS: These studies highlight the importance of molecular docking | ||
| 520 | |a CONCLUSION: Quantitative Structure-Activity Relationship (QSAR) and computer aided drug design (CADD) in predicting of possible pharmacological activities of these targets | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a AMPA | |
| 650 | 4 | |a Cav | |
| 650 | 4 | |a GAT1 | |
| 650 | 4 | |a KCNQ | |
| 650 | 4 | |a Molecular docking | |
| 650 | 4 | |a NMDA | |
| 650 | 4 | |a Nav e GABAA | |
| 650 | 7 | |a Receptors, AMPA |2 NLM | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a gamma-Aminobutyric Acid |2 NLM | |
| 650 | 7 | |a 56-12-2 |2 NLM | |
| 700 | 1 | |a de Moura, Jéssica Paiva |e verfasserin |4 aut | |
| 700 | 1 | |a Dos Santos, Aline Matilde Ferreira |e verfasserin |4 aut | |
| 700 | 1 | |a Monteiro, Alex France M |e verfasserin |4 aut | |
| 700 | 1 | |a Lopes, Simone Mendes |e verfasserin |4 aut | |
| 700 | 1 | |a Scotti, Marcus Tullius |e verfasserin |4 aut | |
| 700 | 1 | |a Scotti, Luciana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug targets |d 2000 |g 24(2023), 3 vom: 27., Seite 212-224 |w (DE-627)NLM113669291 |x 1873-5592 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:3 |g day:27 |g pages:212-224 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389450123666220927103715 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 3 |b 27 |h 212-224 | ||